{"entity":{"type":"insider","cik":"0001559570","url":"/insider/0001559570","json_url":"/insider/0001559570.json","name":"Shapiro David","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":171,"n_filings":68,"first":"2013-04-11","last":"2019-05-03","span_basis":"filed_date"},"name_variants":[{"name":"Shapiro David","source":"filing","n_filings":68,"first_seen":"2013-04-11","last_seen":"2019-05-03"}],"transactions":[{"id":8156890,"accession":"0001144204-19-023712","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-023712","line_url":"/filing/0001144204-19-023712#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":86.28,"price_display":"86.28","price_state":"stated","total_value":172560.0,"total_display":"172,560.00","total_whole":"172,560","shares_owned_after":39499.0,"shares_owned_after_display":"39,499","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-01","filed_date":"2019-05-03","scope":"insider"},{"id":8592845,"accession":"0001144204-19-019949","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-019949","line_url":"/filing/0001144204-19-019949#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":95.0,"price_display":"95.00","price_state":"stated","total_value":190000.0,"total_display":"190,000.00","total_whole":"190,000","shares_owned_after":39499.0,"shares_owned_after_display":"39,499","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-15","filed_date":"2019-04-16","scope":"insider"},{"id":7954071,"accession":"0001144204-19-018081","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-018081","line_url":"/filing/0001144204-19-018081#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":562.0,"shares_display":"562","price_per_share":115.01,"price_display":"115.01","price_state":"stated","total_value":64635.62,"total_display":"64,635.62","total_whole":"64,636","shares_owned_after":39499.0,"shares_owned_after_display":"39,499","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-03","filed_date":"2019-04-03","scope":"insider"},{"id":8447922,"accession":"0001144204-19-011719","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-011719","line_url":"/filing/0001144204-19-011719#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":103.16,"price_display":"103.16","price_state":"stated","total_value":206320.0,"total_display":"206,320.00","total_whole":"206,320","shares_owned_after":40543.0,"shares_owned_after_display":"40,543","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-01","filed_date":"2019-03-01","scope":"insider"},{"id":8769731,"accession":"0001144204-19-009186","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-009186","line_url":"/filing/0001144204-19-009186#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":111.51,"price_display":"111.51","price_state":"stated","total_value":223020.0,"total_display":"223,020.00","total_whole":"223,020","shares_owned_after":40543.0,"shares_owned_after_display":"40,543","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-15","filed_date":"2019-02-20","scope":"insider"},{"id":8385747,"accession":"0001144204-19-000723","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-000723","line_url":"/filing/0001144204-19-000723#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":474.0,"shares_display":"474","price_per_share":97.48,"price_display":"97.48","price_state":"stated","total_value":46205.52,"total_display":"46,205.52","total_whole":"46,206","shares_owned_after":37243.0,"shares_owned_after_display":"37,243","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-04","filed_date":"2019-01-04","scope":"insider"},{"id":8737083,"accession":"0001144204-19-000502","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-19-000502","line_url":"/filing/0001144204-19-000502#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":699.0,"shares_display":"699","price_per_share":97.45,"price_display":"97.45","price_state":"stated","total_value":68117.55,"total_display":"68,117.55","total_whole":"68,118","shares_owned_after":37717.0,"shares_owned_after_display":"37,717","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-03","filed_date":"2019-01-03","scope":"insider"},{"id":8737079,"accession":"0001144204-19-000502","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-000502","line_url":"/filing/0001144204-19-000502#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":98.28,"price_display":"98.28","price_state":"stated","total_value":196560.0,"total_display":"196,560.00","total_whole":"196,560","shares_owned_after":38416.0,"shares_owned_after_display":"38,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-02","filed_date":"2019-01-03","scope":"insider"},{"id":6390929,"accession":"0001144204-18-065469","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-18-065469","line_url":"/filing/0001144204-18-065469#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":106.62,"price_display":"106.62","price_state":"stated","total_value":213240.0,"total_display":"213,240.00","total_whole":"213,240","shares_owned_after":39152.0,"shares_owned_after_display":"39,152","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-17","filed_date":"2018-12-19","scope":"insider"},{"id":6788773,"accession":"0001144204-18-057130","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-18-057130","line_url":"/filing/0001144204-18-057130#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":96.32,"price_display":"96.32","price_state":"stated","total_value":192640.0,"total_display":"192,640.00","total_whole":"192,640","shares_owned_after":39152.0,"shares_owned_after_display":"39,152","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-01","filed_date":"2018-11-02","scope":"insider"},{"id":6347595,"accession":"0001144204-18-054076","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-18-054076","line_url":"/filing/0001144204-18-054076#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3425.0,"shares_display":"3,425","price_per_share":102.95,"price_display":"102.95","price_state":"stated","total_value":352603.75,"total_display":"352,603.75","total_whole":"352,604","shares_owned_after":39152.0,"shares_owned_after_display":"39,152","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-15","filed_date":"2018-10-16","scope":"insider"},{"id":6251631,"accession":"0001144204-18-052813","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-052813","line_url":"/filing/0001144204-18-052813#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":759.0,"shares_display":"759","price_per_share":110.65,"price_display":"110.65","price_state":"stated","total_value":83983.35,"total_display":"83,983.35","total_whole":"83,983","shares_owned_after":39152.0,"shares_owned_after_display":"39,152","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-05","filed_date":"2018-10-05","scope":"insider"},{"id":6490144,"accession":"0001144204-18-048620","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-048620","line_url":"/filing/0001144204-18-048620#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4917.0,"shares_display":"4,917","price_per_share":111.428,"price_display":"111.43","price_state":"stated","total_value":547891.476,"total_display":"547,891.48","total_whole":"547,891","shares_owned_after":42196.0,"shares_owned_after_display":"42,196","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-05","filed_date":"2018-09-07","scope":"insider"},{"id":5075572,"accession":"0001144204-17-051414","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-051414","line_url":"/filing/0001144204-17-051414#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":349.0,"shares_display":"349","price_per_share":58.8983,"price_display":"58.90","price_state":"stated","total_value":20555.5067,"total_display":"20,555.51","total_whole":"20,556","shares_owned_after":44213.0,"shares_owned_after_display":"44,213","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-02","filed_date":"2017-10-04","scope":"insider"},{"id":5330832,"accession":"0001144204-17-046676","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-17-046676","line_url":"/filing/0001144204-17-046676#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1250.0,"shares_display":"1,250","price_per_share":117.43,"price_display":"117.43","price_state":"stated","total_value":146787.5,"total_display":"146,787.50","total_whole":"146,788","shares_owned_after":44562.0,"shares_owned_after_display":"44,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-01","filed_date":"2017-09-05","scope":"insider"},{"id":4949543,"accession":"0001144204-17-040073","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-17-040073","line_url":"/filing/0001144204-17-040073#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1118.0,"shares_display":"1,118","price_per_share":119.0,"price_display":"119.00","price_state":"stated","total_value":133042.0,"total_display":"133,042.00","total_whole":"133,042","shares_owned_after":44562.0,"shares_owned_after_display":"44,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-08-01","filed_date":"2017-08-02","scope":"insider"},{"id":4819355,"accession":"0001144204-17-036753","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-036753","line_url":"/filing/0001144204-17-036753#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":553.0,"shares_display":"553","price_per_share":124.01,"price_display":"124.01","price_state":"stated","total_value":68577.53,"total_display":"68,577.53","total_whole":"68,578","shares_owned_after":44562.0,"shares_owned_after_display":"44,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-11","filed_date":"2017-07-13","scope":"insider"},{"id":5022864,"accession":"0001144204-17-035812","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-17-035812","line_url":"/filing/0001144204-17-035812","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":350.0,"shares_display":"350","price_per_share":121.24285714285715,"price_display":"121.24","price_state":"stated","total_value":42435.0,"total_display":"42,435.00","total_whole":"42,435","shares_owned_after":45215.0,"shares_owned_after_display":"45,215","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-05","scope":"insider","n_lines":2},{"id":4789179,"accession":"0001144204-17-024326","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-17-024326","line_url":"/filing/0001144204-17-024326#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1117.0,"shares_display":"1,117","price_per_share":112.18,"price_display":"112.18","price_state":"stated","total_value":125305.06,"total_display":"125,305.06","total_whole":"125,305","shares_owned_after":45465.0,"shares_owned_after_display":"45,465","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-01","filed_date":"2017-05-03","scope":"insider"},{"id":4500369,"accession":"0001144204-17-020065","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-020065","line_url":"/filing/0001144204-17-020065#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":558.0,"shares_display":"558","price_per_share":108.51,"price_display":"108.51","price_state":"stated","total_value":60548.58,"total_display":"60,548.58","total_whole":"60,549","shares_owned_after":45465.0,"shares_owned_after_display":"45,465","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-10","filed_date":"2017-04-11","scope":"insider"},{"id":5224490,"accession":"0001144204-17-019295","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-019295","line_url":"/filing/0001144204-17-019295#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":346.0,"shares_display":"346","price_per_share":114.9973,"price_display":"115.00","price_state":"stated","total_value":39789.0658,"total_display":"39,789.07","total_whole":"39,789","shares_owned_after":46023.0,"shares_owned_after_display":"46,023","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-03","filed_date":"2017-04-05","scope":"insider"},{"id":4594730,"accession":"0001144204-17-012809","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-17-012809","line_url":"/filing/0001144204-17-012809#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1350.0,"shares_display":"1,350","price_per_share":128.66,"price_display":"128.66","price_state":"stated","total_value":173691.0,"total_display":"173,691.00","total_whole":"173,691","shares_owned_after":46369.0,"shares_owned_after_display":"46,369","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-01","filed_date":"2017-03-03","scope":"insider"},{"id":4090636,"accession":"0001144204-17-001887","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-001887","line_url":"/filing/0001144204-17-001887#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1565.0,"shares_display":"1,565","price_per_share":106.01,"price_display":"106.01","price_state":"stated","total_value":165905.65,"total_display":"165,905.65","total_whole":"165,906","shares_owned_after":40369.0,"shares_owned_after_display":"40,369","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-09","filed_date":"2017-01-11","scope":"insider"},{"id":4287074,"accession":"0001144204-17-000940","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-000940","line_url":"/filing/0001144204-17-000940#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":988.0,"shares_display":"988","price_per_share":103.9191,"price_display":"103.92","price_state":"stated","total_value":102672.0708,"total_display":"102,672.07","total_whole":"102,672","shares_owned_after":41934.0,"shares_owned_after_display":"41,934","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-03","filed_date":"2017-01-05","scope":"insider"},{"id":2090146,"accession":"0001144204-16-138201","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-138201","line_url":"/filing/0001144204-16-138201#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1350.0,"shares_display":"1,350","price_per_share":99.75,"price_display":"99.75","price_state":"stated","total_value":134662.5,"total_display":"134,662.50","total_whole":"134,663","shares_owned_after":42922.0,"shares_owned_after_display":"42,922","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-12-02","filed_date":"2016-12-06","scope":"insider"},{"id":3048452,"accession":"0001144204-16-127903","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-127903","line_url":"/filing/0001144204-16-127903#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":411.0,"shares_display":"411","price_per_share":153.34,"price_display":"153.34","price_state":"stated","total_value":63022.74,"total_display":"63,022.74","total_whole":"63,023","shares_owned_after":44272.0,"shares_owned_after_display":"44,272","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-10","filed_date":"2016-10-12","scope":"insider"},{"id":3342492,"accession":"0001144204-16-127098","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-16-127098","line_url":"/filing/0001144204-16-127098","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1513.0,"shares_display":"1,513","price_per_share":163.07505029742234,"price_display":"163.08","price_state":"stated","total_value":246732.5511,"total_display":"246,732.55","total_whole":"246,733","shares_owned_after":44846.0,"shares_owned_after_display":"44,846","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-03","filed_date":"2016-10-05","scope":"insider","n_lines":2},{"id":2671898,"accession":"0001144204-16-125866","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-16-125866","line_url":"/filing/0001144204-16-125866","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3545.0,"shares_display":"3,545","price_per_share":165.07748544428773,"price_display":"165.08","price_state":"stated","total_value":585199.6859,"total_display":"585,199.69","total_whole":"585,200","shares_owned_after":45732.0,"shares_owned_after_display":"45,732","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-26","filed_date":"2016-09-28","scope":"insider","n_lines":2},{"id":2646264,"accession":"0001144204-16-112100","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-112100","line_url":"/filing/0001144204-16-112100#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":163.0,"shares_display":"163","price_per_share":145.1092,"price_display":"145.11","price_state":"stated","total_value":23652.7996,"total_display":"23,652.80","total_whole":"23,653","shares_owned_after":48391.0,"shares_owned_after_display":"48,391","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-07","scope":"insider"},{"id":2441276,"accession":"0001144204-16-093113","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-093113","line_url":"/filing/0001144204-16-093113#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":165.0,"shares_display":"165","price_per_share":130.76,"price_display":"130.76","price_state":"stated","total_value":21575.4,"total_display":"21,575.40","total_whole":"21,575","shares_owned_after":48546.0,"shares_owned_after_display":"48,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-04","filed_date":"2016-04-06","scope":"insider"},{"id":3284151,"accession":"0001144204-16-074238","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-16-074238","line_url":"/filing/0001144204-16-074238","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":533.0,"shares_display":"533","price_per_share":145.9037,"price_display":"145.90","price_state":"stated","total_value":77766.6721,"total_display":"77,766.67","total_whole":"77,767","shares_owned_after":40911.0,"shares_owned_after_display":"40,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-04","filed_date":"2016-01-05","scope":"insider","n_lines":2},{"id":8781888,"accession":"0001144204-15-071586","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-15-071586","line_url":"/filing/0001144204-15-071586","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500.0,"shares_display":"3,500","price_per_share":157.40007142857144,"price_display":"157.40","price_state":"stated","total_value":550900.25,"total_display":"550,900.25","total_whole":"550,900","shares_owned_after":29395.0,"shares_owned_after_display":"29,395","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-15","filed_date":"2015-12-17","scope":"insider","n_lines":2},{"id":8683550,"accession":"0001144204-15-066821","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-15-066821","line_url":"/filing/0001144204-15-066821","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4264.0,"shares_display":"4,264","price_per_share":178.52655412757974,"price_display":"178.53","price_state":"stated","total_value":761237.2268,"total_display":"761,237.23","total_whole":"761,237","shares_owned_after":29895.0,"shares_owned_after_display":"29,895","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-16","filed_date":"2015-11-18","scope":"insider","n_lines":2},{"id":8810163,"accession":"0001144204-15-064920","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-064920","line_url":"/filing/0001144204-15-064920#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500.0,"shares_display":"3,500","price_per_share":204.15,"price_display":"204.15","price_state":"stated","total_value":714525.0,"total_display":"714,525.00","total_whole":"714,525","shares_owned_after":29159.0,"shares_owned_after_display":"29,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-10","filed_date":"2015-11-12","scope":"insider"},{"id":8701378,"accession":"0001144204-15-058165","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-15-058165","line_url":"/filing/0001144204-15-058165#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":858.0,"shares_display":"858","price_per_share":159.0393,"price_display":"159.04","price_state":"stated","total_value":136455.7194,"total_display":"136,455.72","total_whole":"136,456","shares_owned_after":29159.0,"shares_owned_after_display":"29,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-02","filed_date":"2015-10-05","scope":"insider"},{"id":8701375,"accession":"0001144204-15-058165","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-15-058165","line_url":"/filing/0001144204-15-058165#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":282.0,"shares_display":"282","price_per_share":163.39,"price_display":"163.39","price_state":"stated","total_value":46075.98,"total_display":"46,075.98","total_whole":"46,076","shares_owned_after":30017.0,"shares_owned_after_display":"30,017","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-01","filed_date":"2015-10-05","scope":"insider"},{"id":8906449,"accession":"0001144204-15-055546","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001144204-15-055546","line_url":"/filing/0001144204-15-055546","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500.0,"shares_display":"3,500","price_per_share":191.28008571428572,"price_display":"191.28","price_state":"stated","total_value":669480.3,"total_display":"669,480.30","total_whole":"669,480","shares_owned_after":23527.0,"shares_owned_after_display":"23,527","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-09-15","filed_date":"2015-09-17","scope":"insider","n_lines":3},{"id":8403185,"accession":"0001144204-15-050873","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-050873","line_url":"/filing/0001144204-15-050873#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4272.0,"shares_display":"4,272","price_per_share":209.37,"price_display":"209.37","price_state":"stated","total_value":894428.64,"total_display":"894,428.64","total_whole":"894,429","shares_owned_after":18233.0,"shares_owned_after_display":"18,233","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-08-17","filed_date":"2015-08-19","scope":"insider"},{"id":8062166,"accession":"0001144204-15-041467","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-15-041467","line_url":"/filing/0001144204-15-041467","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":851.0,"shares_display":"851","price_per_share":236.2897473560517,"price_display":"236.29","price_state":"stated","total_value":201082.575,"total_display":"201,082.58","total_whole":"201,083","shares_owned_after":19055.0,"shares_owned_after_display":"19,055","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-02","filed_date":"2015-07-07","scope":"insider","n_lines":3},{"id":8800631,"accession":"0001144204-15-041253","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001144204-15-041253","line_url":"/filing/0001144204-15-041253#line-6","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001559570","owner_name":"Shapiro David","owner_display_name":"Shapiro David","owner_url":"/insider/0001559570","role":"Officer (CMO and EVP - Development)","role_mark":"O","role_mark_label":"Officer (CMO and EVP - Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CMO and EVP - Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1902.0,"shares_display":"1,902","price_per_share":238.5076,"price_display":"238.51","price_state":"stated","total_value":453641.4552,"total_display":"453,641.46","total_whole":"453,641","shares_owned_after":19112.0,"shares_owned_after_display":"19,112","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-01","filed_date":"2015-07-06","scope":"insider"}],"collapsed":true,"next_cursor":"2015-07-01|8800631","ledger_fault":false,"count":{"value":171,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":171,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":171},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001270073","name":"INTERCEPT PHARMACEUTICALS, INC.","url":"/issuer/0001270073","role":"Officer (Chief Medical Officer)","n_filings":68,"first_seen":"2013-04-11","last_seen":"2019-05-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001559570","retrieved_at":"2026-08-24T12:00:46+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}